Equities Analysts Issue Forecasts for SNDX FY2027 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analysts at B. Riley upped their FY2027 EPS estimates for Syndax Pharmaceuticals in a research note issued on Monday, October 27th. B. Riley analyst M. Mamtani now expects that the company will post earnings of $0.06 per share for the year, up from their previous estimate of $0.05. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.18. The business had revenue of $37.96 million for the quarter, compared to analysts’ expectations of $26.64 million. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The company’s revenue was up 984.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.80) EPS.

Other research analysts also recently issued reports about the company. Stifel Nicolaus started coverage on Syndax Pharmaceuticals in a research note on Wednesday, September 10th. They set a “buy” rating and a $44.00 price objective for the company. Citigroup upped their price target on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Guggenheim initiated coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, September 4th. They issued a “buy” rating and a $34.00 price objective for the company. The Goldman Sachs Group raised their price objective on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, September 5th. Finally, UBS Group dropped their target price on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Syndax Pharmaceuticals Price Performance

Shares of Syndax Pharmaceuticals stock opened at $13.39 on Thursday. The stock has a market cap of $1.15 billion, a P/E ratio of -3.44 and a beta of 0.68. The company has a debt-to-equity ratio of 2.06, a quick ratio of 4.55 and a current ratio of 4.71. The stock’s fifty day moving average is $15.42 and its 200 day moving average is $12.53. Syndax Pharmaceuticals has a one year low of $8.58 and a one year high of $22.50.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its holdings in shares of Syndax Pharmaceuticals by 33.7% in the second quarter. Bank of America Corp DE now owns 3,838,872 shares of the company’s stock worth $35,951,000 after purchasing an additional 967,873 shares during the last quarter. Qube Research & Technologies Ltd boosted its stake in Syndax Pharmaceuticals by 99.5% during the second quarter. Qube Research & Technologies Ltd now owns 1,665,916 shares of the company’s stock valued at $15,601,000 after buying an additional 831,067 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in Syndax Pharmaceuticals by 126.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,432,440 shares of the company’s stock valued at $13,415,000 after buying an additional 800,800 shares in the last quarter. Stempoint Capital LP increased its stake in Syndax Pharmaceuticals by 48.4% in the 2nd quarter. Stempoint Capital LP now owns 2,372,634 shares of the company’s stock worth $22,220,000 after acquiring an additional 774,040 shares during the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $3,568,000.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, Director Dennis Podlesak sold 19,200 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $15.84, for a total transaction of $304,128.00. Following the completion of the transaction, the director directly owned 191,763 shares of the company’s stock, valued at approximately $3,037,525.92. This trade represents a 9.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Metzger sold 157,307 shares of Syndax Pharmaceuticals stock in a transaction on Monday, September 8th. The shares were sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the completion of the sale, the chief executive officer owned 298,661 shares in the company, valued at approximately $4,901,027.01. This represents a 34.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 195,707 shares of company stock worth $3,183,904 in the last three months. Insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).